Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor-positive operable breast cancer

Oncologist

Volumn 12, Issue 10, 2007, Pages 1156-1164

  Jones, Lee W ^a   Haykowsky, Mark ^b   Pituskin, Edith N ^c   Jendzjowsky, Nick G ^b   Tomczak, Corey R ^b   Haennel, Robert G ^b   Mackey, John R ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

Adjuvant therapy; Cardiovascular reserve; Cardiovascular risk profile; Early breast cancer

Indexed keywords

ANTHRACYCLINE; ANTIHYPERTENSIVE AGENT; AROMATASE INHIBITOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HORMONE RECEPTOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AEROBIC CAPACITY; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GAS ANALYSIS; HEART OUTPUT; HEART STROKE VOLUME; HORMONAL THERAPY; HUMAN; IMPEDANCE CARDIOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART; HEART FUNCTION TESTS; HUMANS; MIDDLE AGED; OXYGEN CONSUMPTION; PILOT PROJECTS; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; TAMOXIFEN;

EID: 36148936367     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-10-1156     Document Type: Article

References (47)

1. Floyd JD, Nguyen DT, Lobins RL et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685-7696.
2. Darby S, McGale P, Peto R et al. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: Nationwide cohort study of 90 000 Swedish women. BMJ 2003;326:256-257.
3. Giordano SH, Kuo YF, Freeman JL et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005;97:419-424.
4. Patt DA, Goodwin JS, Kuo YF et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005;23:7475-7482.
5. Das SK, Baydush AH, Zhou S et al. Predicting radiotherapy-induced cardiac perfusion defects. Med Phys 2005;32:19-27.
6. Marks LB, Yu X, Prosnitz RG et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005;63:214-223.
7. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005;32(suppl 3):S71-S80.
8. Adams MJ, Hardenbergh PH, Constine LS et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003;45:55-75.
9. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-7826.
10. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-2027.
11. Bonneterre J, Roche H, Kerbrat P et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004;22:3070-3079.
12. Perez EA, Suman VJ, Davidson NE et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22:3700-3704.
13. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-2313.
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
15. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
16. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
17. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
18. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
19. Thurlimann B, Keshaviah A, Coates AS et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
20. Sacco M, Valentini M, Belfiglio M et al. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01. J Clin Oncol 2003;21:2276-2281.
21. Draper MW. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann N Y Acad Sci 2003;997:373-377.
22. Costantino JP, Kuller LH, Ives DG et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776-782.
23. Nordenskjold B, Rosell J, Rutqvist LE et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial. J Natl Cancer Inst 2005;97:1609-1610.
24. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women. Breast 2006;15:301-312.
25. Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 1993;85:979-987.
26. Yancik R, Wesley MN, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
27. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754.
28. Civelli M, Cardinale D, Martinoni A et al. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 2006;111:120-126.
29. Ross RM. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-277.
30. Bernstein DP, Lemmens HJ. Stroke volume equation for impedance cardiography. Med Biol Eng Comput 2005;43:443-450.
31. Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139-3148.
32. Jones LW, Haykowsky M, Peddle CJ et al. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane- containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev 2007;16:1026-1031.
33. Gulati M, Pandey DK, Arnsdorf MF et al. Exercise capacity and the risk of death in women: The St James Women Take Heart Project. Circulation 2003;108:1554-1559.
34. Mora S, Redberg RF, Cui Y et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: A 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003;290:1600-1607.
35. Paterson DH, Cunningham DA, Koval JJ et al. Aerobic fitness in a population of independently living men and women aged 55-86 years. Med Sci Sports Exerc 1999;31:1813-1820.
36. Erikssen G, Liestol K, Bjornholt J et al. Changes in physical fitness and changes in mortality. Lancet 1998;352:759-762.
37. Aaronson KD, Mancini DM. Is percentage of predicted maximal exercise oxygen consumption a better predictor of survival than peak exercise oxygen consumption for patients with severe heart failure? J Heart Lung Transplant 1995;14:981-989.
38. Tanaka H, Desouza CA, Jones PP et al. Greater rate of decline in maximal aerobic capacity with age in physically active vs. sedentary healthy women. J Appl Physiol 1997;83:1947-1953.
39. Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005;150:977-982.
40. Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-2636.
41. Tassan-Mangina S, Codorean D, Metivier M et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7:141-146.
42. Jones LW, Haykowsky M, Swartz J et al. Operable breast cancer therapy, cardiovascular injury and the 'multiple hit' hypothesis: The role of aerobic exercise training. J Am Coll Cardiol, submitted
43. Tan LB. Cardiac pumping capability and prognosis in heart failure. Lancet 1986;2:1360-1363.
44. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol 1993;11:1418-1429.
45. Irwin ML, McTiernan A, Baumgartner RN et al. Changes in body fat and weight after a breast cancer diagnosis: Influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 2005;23:774-782.
46. Irwin ML, McTiernan A, Bernstein L et al. Physical activity levels among breast cancer survivors. Med Sci Sports Exerc 2004;36:1484-1491.
47. Jones LW, Eves ND, Mackey JR et al. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer 2007;55:225-232.